PDCD1 and neoplasm: Furthermore, in a phase 2 basket trial of anti-PD-1 monotherapy with pembrolizumab, all five enrolled patients with RMC consistently showed progressive disease, with a median time to progression of only 8.7 weeks, irrespective of PD-L1 expression or tumor-infiltrating lymphocyte (TIL) levels13.